PROJECT SUMMARY
Malaria remains a global health problem, with nearly half the world’s population at risk of transmission. Of the
many clinical outcomes of malaria, cerebral malaria is the major cause of death in children. Cerebral malaria is
caused by the accumulation of infected erythrocytes in brain capillaries, resulting in reduced blood flow, lesions,
brain swelling, and ultimately coma and death. The adhesion of infected erythrocytes to host receptors found on
brain endothelium is facilitated by the variant surface antigen Plasmodium falciparum erythrocyte membrane
protein 1 (PfEMP1). Specifically, cysteine-rich interdomain region alpha 1 (CIDRa1) domains in PfEMP1 mediate
binding to host endothelial protein C receptor (EPCR). Children in malaria-endemic regions who overcome the
initial clinical complications of the disease rapidly develop immunity against cerebral malaria, resulting from the
acquisition of antibodies targeting CIDRa1. Given the high sequence variation among CIDRa1 variants and the
quick waning of antibody responses against other P. falciparum proteins, it is unclear how this protection is
achieved and maintained over time. Our preliminary work has revealed that monoclonal antibodies from malaria-
protected adults can recognize multiple CIDRa1 variants despite their sequence diversity and inhibit the binding
of these CIDRa1 variants to EPCR. We also observed that a substantial percentage of CIDRa1-targeting B cells
possessed an atypical B cell phenotype. Based on our preliminary data, we hypothesize that broadly reactive
antibodies against CIDRa1 target diverse epitopes around the EPCR-binding site and are generated in
conjunction with long-lasting B cell memory. In Specific Aim 1, we will isolate monoclonal antibodies against
CIDRa1 from memory B cells of malaria protected adults to elucidate the diversity and epitopes of broad and
variant specific antibodies. In Specific Aim 2, we will define the phenotype and maintenance of CIDRa1-specific
B cells using high parameter spectral flow cytometry on longitudinal peripheral blood mononuclear cell samples.
The results from this study will enhance our understanding of the nature and durability of protective immunity
and advance the design of a vaccine that elicits broad and long-lived protection against malaria pathogenesis.
